Global Insights in Biomedical & Multidisciplinary Research (GIBMR)
Volume 01, Issue 02, April-2026
Available Online at: https://biomedglobe.com/index.php/gibmr
ISSN (Online): 3054-5900

# Modern Theories On The Pathogenesis Of Benign Prostatic Hyperplasia: A Narrative Review

[1]Khudayberdiev Kh.B., [2]Soliev T.Kh.
[1]Tashkent State Medical University
[2]Republican Specialized Scientific and Practical Medical Center of Urology

**Article History**

Received: 11th February, 2026
Accepted: 10th March, 2026

**Abstract**

**Background**. BPH is one of the most common urological conditions in aging men. What's changed over the past two decades is not the clinical picture — men still come in with the same obstructive symptoms — but our understanding of why the prostate enlarges. The androgen-centric model that shaped treatment for decades is correct as far as it goes; it just doesn't go far enough.

**Objectives**. To review and integrate current evidence on the major pathogenic theories of BPH — hormonal, inflammatory, stromal-epithelial, stem cell, metabolic, oxidative stress, genetic, neuroendocrine, and microbiome-related — and to consider their therapeutic implications and the questions that remain genuinely open.

**Methods**. A narrative review was conducted in accordance with established quality criteria [28]. PubMed/MEDLINE, Scopus, and Web of Science were searched for peer-reviewed English-language publications. Foundational studies were included regardless of date; for emerging mechanisms (metabolic syndrome, epigenetics, microbiome), publications from 2015 onwards were prioritized. Twenty-four primary sources were included.

**Results**. BPH pathogenesis is multifactorial. Androgens — principally dihydrotestosterone (DHT) — provide the foundational proliferative stimulus, but chronic low-grade inflammation, stromal-epithelial growth factor signaling, stem cell dysregulation, metabolic syndrome, oxidative stress, and neuroendocrine inputs each contribute independently and in combination. The urinary microbiome may be an additional modulatory factor, though the evidence is early. No single pathway fully explains disease initiation or progression. Hormonal and inflammatory pathways are supported by clinical trial data; metabolic, epigenetic, and microbiome contributions rest predominantly on observational and preclinical evidence — a distinction that matters clinically.

Global Insights in Biomedical & Multidisciplinary Research (GIBMR)
Volume 01, Issue 02, April-2026
Available Online at: https://biomedglobe.com/index.php/gibmr
ISSN (Online): 3054-5900

**Conclusion**. Treating BPH as a single-pathway disease is probably why so many men have inadequate responses to current therapy. Combination strategies targeting hormonal, inflammatory, and metabolic mechanisms simultaneously are a logical next step. Validated biomarkers to identify which combination a given patient needs are the obvious gap.

**Keywords:** Benign prostatic hyperplasia; BPH pathogenesis; chronic prostatic inflammation; dihydrotestosterone; stromal-epithelial interaction; metabolic syndrome; oxidative stress; urinary microbiome

## 1. Introduction

### 1.1 Epidemiology

Histological evidence of prostatic hyperplasia appears in approximately 50% of men by age 60 and in up to 90% by age 85 [1]. Those numbers are striking, though it's worth noting that histological BPH and clinically significant disease are not the same thing — roughly half of men with histological changes develop lower urinary tract symptoms (LUTS) severe enough to affect quality of life [1, 3]. The economic burden is real and diffuse: diagnostic workup, long-term pharmacotherapy, surgical intervention, lost sleep, sexual dysfunction, lost productivity [1, 2].

As populations age, BPH prevalence will keep rising [4]. This is not a condition medicine can afford to understand only partially.

### 1.2 Clinical Significance and Disease Burden

Untreated BPH can progress to acute urinary retention, recurrent urinary tract infections, bladder stones, hydronephrosis, and renal insufficiency [3]. Its associations with metabolic syndrome, cardiovascular disease, and sexual dysfunction are worth pausing on — they suggest BPH is a systemic condition that happens to express itself in the prostate, not a local anomaly [4]. Current pharmacological treatments (alpha-blockers, 5-ARIs, PDE5 inhibitors) address one or two pathogenic pathways at most [27]. The substantial proportion of men who respond inadequately or whose responses diminish over time is the clearest argument for rethinking the mechanistic model [2].

### 1.3 Evolution of Pathogenic Understanding

The androgen-centric model — DHT drives prostatic growth through androgen receptor activation — is clinically valid and still the basis of first-line therapy. It just can't account for everything we observe. Over the past two decades, chronic low-grade inflammation, stromal-epithelial paracrine signaling, stem cell dysregulation, metabolic syndrome, oxidative stress, and neuroendocrine mechanisms have each been identified as independent contributors [6, 7]. The picture that emerges is less elegant than a single-pathway model, but probably more honest.

## 2. Methods

Literature searches were performed between January and March 2026 in PubMed/MEDLINE, Scopus, and Web of Science. Search terms included "benign

prostatic hyperplasia," "BPH pathogenesis," "prostate inflammation," "stromal-epithelial interaction," "stem cell prostate," "metabolic syndrome prostate," "oxidative stress prostate," "BPH genetics," "adrenergic receptor prostate," "urinary microbiome," and their Boolean combinations. English-language peer-reviewed articles were eligible. Foundational studies were included regardless of publication date; for emerging fields — metabolic syndrome, epigenetics, microbiome — publications from 2015 onwards were prioritized. Editorials, conference abstracts, and non-peer-reviewed commentary were excluded. Twenty-eight sources were selected based on relevance to the pathogenic mechanisms reviewed. The review follows established quality criteria for narrative reviews [28].

## 3. Hormonal Theory

### 3.1 Androgens and Clinical Validation

Testosterone is converted within prostatic tissue to dihydrotestosterone (DHT) by 5-alpha reductase (5-AR), which exists as two isoforms: SRD5A1 and SRD5A2 [1, 9]. DHT binds the androgen receptor with approximately five-fold greater affinity than testosterone and is the principal androgen responsible for prostatic growth throughout life [10]. In both stromal and epithelial compartments, androgen receptor activation triggers transcriptional programs that promote cellular proliferation, suppress apoptosis, and stimulate growth factor production [1].

The clinical efficacy of 5-ARIs is the strongest evidence we have for the centrality of DHT. Finasteride (selective SRD5A2 inhibitor) and dutasteride (dual inhibitor) reduce intraprostatic DHT by up to 90%, producing 20–30% reductions in prostate volume over 6–12 months [9, 10]. But a meaningful minority of men don't respond adequately to 5-ARI therapy alone — and that clinical reality is itself an argument that the androgen model, however well-validated, is incomplete [1].

### 3.2 Estrogen Involvement

With advancing age, men experience a relative increase in estrogen levels — enhanced peripheral aromatization of androgens in adipose tissue, declining testicular testosterone production [12]. The shift in androgen-to-estrogen ratio appears to contribute to BPH, though the mechanism is more nuanced than simply "more estrogen, more growth."

Estrogen receptor alpha (ERα), predominantly expressed in stromal cells, promotes cellular proliferation and inflammation. Estrogen receptor beta (ERβ), more abundant in epithelial cells, inhibits growth and promotes differentiation [15]. Net effect depends on which receptor predominates in a given tissue compartment. Experimental models show that combined androgen-estrogen administration produces more severe prostatic hyperplasia than androgens alone [1], and estrogens further modulate growth factor expression and inflammatory mediators, amplifying proliferative effects [12, 16]. The full clinical significance of this receptor balance in human BPH is still being worked out.

### 3.3 5-Alpha Reductase and Genetic Variants

SRD5A2 is the dominant isoform in prostatic stromal cells and responsible for most intraprostatic DHT production; SRD5A1 is more widely distributed in skin and liver [9]. Identified polymorphisms in SRD5A2 influence enzyme activity and modify BPH risk across populations [13]. Men with variants conferring higher 5-AR activity show elevated intraprostatic DHT and greater disease susceptibility; those with reduced activity show lower prevalence [10]. This genetic evidence for DHT's causal role is robust, and it is the pharmacological logic behind 5-ARI therapy [9].

### 3.4 Hormonal Interactions with Other Mechanisms

Hormonal factors don't operate in isolation. DHT stimulates production of pro-inflammatory cytokines including IL-6 and TNF-α, which in turn promote stromal proliferation and tissue remodeling [7]. Androgens and estrogens regulate the expression of FGFs, TGF-β, and IGFs — the principal mediators of stromal-epithelial paracrine signaling [1, 22]. The result is a self-amplifying network: hormones drive inflammation, inflammation amplifies hormonal effects, and together they drive disease progression [1, 8].

## 4. Chronic Inflammation Theory

### 4.1 Inflammatory Cell Infiltration and Immune Microenvironment

Chronic inflammation is present histologically in the majority of BPH specimens. For a long time it was treated as an incidental finding; it is now recognized as a central pathogenic mechanism [3, 7]. The inflammatory infiltrate consists predominantly of CD4+ and CD8+ T lymphocytes, B lymphocytes, macrophages, and mast cells distributed throughout stromal and epithelial compartments [9, 16]. This low-grade chronic inflammation creates a pro-proliferative microenvironment — sustained cytokine production, growth factor release, reactive oxygen species (ROS) generation [7, 10].

Prostatic epithelial and stromal cells recruit immune cells by secreting chemokines (CXCL8, CCL2, CCL5) in response to tissue injury or microbial triggers [7]. Once resident, these immune cells release IL-1β, IL-6, TNF-α, and IFN-γ, which stimulate stromal and epithelial proliferation, inhibit apoptosis, and promote tissue remodeling [9, 10].

Macrophage phenotype is worth noting. Both M1 (pro-inflammatory) and M2 (tissue-remodeling) phenotypes are present in hyperplastic prostatic tissue [16]. M1 macrophages produce cytokines and ROS that amplify cellular proliferation; M2 macrophages secrete growth factors and MMPs that drive fibrosis and architectural remodeling. The balance between them may influence how fast the disease progresses [9] — though characterizing that balance reliably in clinical tissue samples remains technically challenging.

### 4.2 Cytokine Networks

IL-6 is elevated in both BPH tissue and serum and correlates with prostate volume and symptom severity [9]. It promotes stromal proliferation, suppresses epithelial apoptosis, and sustains inflammation through JAK-STAT activation [7]. TNF-α activates NF-κB,

MAPK, and AP-1 cascades, increasing expression of adhesion molecules, chemokines, and growth factors while stimulating stromal proliferation and collagen synthesis [7, 10]. IL-8 (CXCL8) is both a chemoattractant and an angiogenic factor through CXCR1/CXCR2 signaling, with a direct contribution to prostatic growth [7, 9].

### 4.3 COX-2 and Prostaglandin Pathways

COX-2 expression is markedly elevated in BPH tissue, particularly in stromal and infiltrating immune cells [2, 7]. COX-2 converts arachidonic acid to prostaglandin E2 (PGE2), which promotes cellular proliferation, suppresses apoptosis, stimulates angiogenesis, and drives further cytokine production through EP receptor activation [2, 7]. COX-2-derived prostaglandins also contribute to smooth muscle contraction in the prostatic urethra and bladder neck, potentially worsening LUTS independently of gland volume [7] — a point that matters clinically, since volume and symptoms don't always track together.

Preclinical COX-2 inhibition reduces prostatic inflammation and slows BPH development in animal models [2]. Clinical translation has stalled because of cardiovascular and gastrointestinal safety concerns — a frustrating situation given the mechanistic plausibility of this target [7].

### 4.4 NF-κB Signaling

NF-κB is significantly activated in BPH tissue, with nuclear localization of the p65 subunit in both stromal and epithelial compartments [2, 7]. TNF-α, IL-1β, ROS, and hormonal signals all converge on NF-κB activation, which then induces COX-2, iNOS, and additional pro-inflammatory cytokines [2] — a cycle that sustains the pro-proliferative microenvironment without requiring a persistent external trigger. Preclinical NF-κB inhibition reduces prostatic inflammation and cellular proliferation [2, 7]. Natural compounds including piceatannol, curcumin, and resveratrol target this pathway and show preclinical promise, though clinical translation remains limited [2]. What makes NF-κB particularly interesting is that it integrates oxidative stress with hormonal signaling through androgen receptor crosstalk, positioning it as a convergence point for multiple pathogenic inputs [2, 7].

### 4.5 Inflammation and Tissue Remodeling

Chronic inflammation does more than proliferate cells — it remodels tissue. TGF-β-mediated differentiation of fibroblasts into myofibroblasts leads to excessive collagen and extracellular matrix deposition [7, 9]. This increases prostatic stiffness and alters tissue compliance, which can worsen bladder outlet obstruction independently of gland volume [7]. Dysregulation of MMPs and their inhibitors (TIMPs) favors net matrix accumulation and progressive architectural distortion [9, 10]. This fibrotic component of BPH is probably underappreciated therapeutically — volume reduction doesn't address it, which may partly explain why symptom relief and volume change correlate imperfectly in clinical trials.

## 5. Stromal-Epithelial Interaction Theory

### 5.1 Paracrine Signaling Networks

BPH appears to begin with a breakdown in communication between prostatic stromal and epithelial cells. Normally they keep each other in check—stromal fibroblasts and smooth muscle cells exchange growth factors and cytokines with epithelial cells, and the exchange holds tissue homeostasis in place. In BPH, that balance tips. Stromal proliferation comes first and is often more pronounced than the epithelial hyperplasia it eventually drags along [1, 11]. DHT-stimulated stromal cells release growth factors that push epithelial cells to proliferate; those epithelial cells signal back to the stroma; the loop becomes self-sustaining [1]. What's worth pausing on here is the temporal sequence: the stroma is the driver, not just a bystander, which has implications for where therapeutic intervention makes most sense.

### 5.2 Fibroblast Growth Factors (FGFs)

FGF2, FGF7, and FGF10 are all elevated in BPH tissue relative to normal prostate, and elevation tracks with disease severity [11]. FGF7 and FGF10, made in stromal cells, bind epithelial FGF receptors and drive epithelial proliferation and survival [1]. FGF2 acts on both compartments and promotes angiogenesis, contributing to overall gland growth [1]. Androgens feed into this by stimulating FGF production in stroma; FGF receptor blockade blunts androgen-driven prostatic growth in animal models, which is about as clean a mechanistic confirmation as this literature tends to offer [11].

### 5.3 Epidermal Growth Factor (EGF) Family

EGF, TGF-α, and amphiregulin all bind EGFR, a receptor tyrosine kinase that triggers MAPK, PI3K/Akt, and STAT signaling [1, 11]. EGFR expression and activation are elevated in BPH epithelium. Stromal cells supply EGF-family ligands that act on epithelial EGFR in paracrine fashion, while autocrine EGFR signaling within epithelium sustains proliferation and apoptotic resistance [11]. Inflammatory cytokines also induce EGFR ligand expression—which is one of several places in this pathophysiology where the inflammatory and growth factor arms reinforce each other rather than operating as separate tracks [1].

### 5.4 Transforming Growth Factor-Beta (TGF-β) Superfamily

TGF-β does different things depending on which cell type you're looking at, and this is one of the more interesting complications in BPH biology. In stroma, it drives proliferation, myofibroblast differentiation, and extracellular matrix deposition—the fibrotic component [23]. In epithelium, TGF-β normally halts growth. Except in established BPH, where that response is blunted or lost entirely, through changes in receptor expression or downstream signaling [1, 11]. The epithelium has, in effect, escaped one of its own brakes. TGF-β also promotes epithelial-mesenchymal transition, which may account for some of the increased stromal cellularity and altered architecture in BPH tissue [1].

### 5.5 Insulin-Like Growth Factors (IGFs)

IGF-1—produced both locally in prostatic tissue and systemically in the liver—drives cell proliferation and survival through IGF-1 receptor activation of PI3K/Akt and

MAPK [22]. IGF-1 receptor expression and signaling are elevated in BPH [22]. Changes in IGF-binding protein expression reduce IGF-1 sequestration, increasing bioavailable IGF-1 and amplifying the proliferative signal [1]. This is one of the more mechanistically specific links between metabolic syndrome and BPH: hyperinsulinemia suppresses hepatic IGFBP production, freeing up more IGF-1, which in turn promotes prostatic cell proliferation [22].

## 6. Stem Cell Theory

### 6.1 Prostatic Stem Cell Populations and Niches

The stem cell theory proposes that BPH is driven, at least partly, by aberrant reactivation of prostatic stem cell populations [5, 20]. The adult prostate carries multiple stem cell populations—basal epithelial stem cells, luminal progenitor cells, and possibly stromal stem cells—housed in niches that regulate self-renewal and differentiation [20]. Single-cell RNA sequencing data from BPH tissue show expanded progenitor populations with stem-like properties: higher proliferative capacity, apoptotic resistance, altered differentiation [20]. These findings from single-cell sequencing are relatively recent and I'd treat the specific claims with some caution until they are better replicated, but the broad picture of dysregulated progenitor activity is consistent across multiple experimental approaches.

Niche-level changes—altered growth factor availability, inflammatory mediators, matrix composition—can push stem cells into inappropriate activation [5]. Age-related niche changes, including senescent cell accumulation and shifted paracrine signals, probably explain part of why BPH prevalence climbs so steeply with age [20].

### 6.2 Embryonic Reawakening Hypothesis

This is the more speculative corner of stem cell theory. The proposal is that BPH involves reactivation of developmental signaling programs—SHH, Wnt, FGFs, BMPs—that normally drive prostatic embryogenesis and are then silenced in adult tissue [5]. Multiple embryonic growth factors and transcription factors are indeed re-expressed in BPH tissue [5]. SHH, which drives prostatic budding in fetal development, is reactivated in BPH and promotes stromal proliferation; Wnt signaling, essential for prostatic morphogenesis, is upregulated and contributes to tissue remodeling [5, 20]. Age-related epigenetic drift and hormonal changes may erode the silencing mechanisms that normally keep these programs off [20]. The evidence is suggestive rather than definitive, and the jump from 're-expression of developmental factors' to 'these are causally driving BPH' is one that the literature hasn't fully bridged yet.

### 6.3 Stem Cell Senescence and Aging

Cellular senescence—irreversible growth arrest paired with the senescence-associated secretory phenotype (SASP)—accumulates in both stromal and epithelial compartments of BPH tissue with age [19]. SASP components, including pro-inflammatory cytokines, growth factors, and MMPs, create a local environment that can paradoxically activate stem cells in neighboring non-senescent cells [5, 19]. There's something counterintuitive about that—cells that have stopped dividing themselves

driving their neighbors to divide. Stem cells also accumulate DNA damage, epigenetic changes, and mitochondrial dysfunction with age, making them more prone to dysregulated activation [5, 20]. Senolytics and senomorphics—drugs that clear senescent cells or suppress their secretory output—have shown early promise in preclinical BPH models [19], though translating senolytic results to humans has proven harder than the preclinical data suggested in other disease contexts.

## 7. Metabolic Syndrome and BPH

### 7.1 Epidemiological Associations

Metabolic syndrome—central obesity, insulin resistance, dyslipidemia, and hypertension—is a well-established risk factor for BPH development and progression [4, 22]. Men with MetS have larger prostate volumes, worse LUTS, and faster disease progression than metabolically healthy men [4, 22]. Risk scales with the number of MetS components present [4]. The parallel rise of global obesity and BPH prevalence implicates modifiable metabolic factors, which is both relevant clinically and, in retrospect, fairly obvious—though it took some time for the field to take this link seriously [4].

### 7.2 Obesity and Adipose Tissue Dysfunction

Visceral fat is an endocrine tissue, secreting leptin, adiponectin, resistin, and inflammatory cytokines [22]. In obesity, adipocyte hypertrophy, tissue hypoxia, and macrophage infiltration produce systemic inflammation that reaches the prostate through circulating mediators [22]. Leptin, elevated in obesity, promotes prostatic cell proliferation and apoptotic resistance through JAK-STAT, MAPK, and PI3K/Akt [22]. Adiponectin—which has anti-inflammatory and anti-proliferative effects—is reduced in obesity, removing a restraining influence [22]. The adiponectin angle deserves more attention than it usually gets; losing a protective signal is mechanistically distinct from gaining a harmful one, and the two aren't interchangeable in terms of therapeutic implications.

Obesity also amplifies aromatase activity in adipose tissue, raising estrogen and shifting the androgen-to-estrogen ratio toward prostatic growth (discussed in Section 3.2) [22]. Elevated circulating IL-6, TNF-α, and CRP contribute directly to inflammatory infiltration of the gland [22].

### 7.3 Insulin Resistance and Hyperinsulinemia

Compensatory hyperinsulinemia directly promotes prostatic cell proliferation [22, 23]. Insulin is structurally similar to IGF-1 and, at elevated concentrations, activates hybrid insulin/IGF-1 receptors, triggering proliferative cascades [22]. Hyperinsulinemia also suppresses hepatic production of IGFBP-1 and IGFBP-2, raising free IGF-1 and the prostatic growth signal [22].

On top of that, hyperinsulinemia suppresses SHBG, increasing free testosterone and estrogen fractions, and upregulates androgen receptor expression and activity in prostatic cells—amplifying the effect of any given androgen concentration [22]. The combination is worth naming plainly: this is not one mechanism but several converging

ones, which is part of why insulin resistance is probably a more important modifiable risk factor for BPH than it appears in most clinical discussions [22].

### 7.4 Dyslipidemia and Lipid Metabolism

Elevated triglycerides, low HDL, and small dense LDL particles affect prostatic growth through inflammation, oxidative stress, and steroid hormone biosynthesis [23]. Cholesterol is the obligate precursor for steroid hormones, and disturbed cholesterol metabolism likely perturbs intraprostatic androgen and estrogen production, though the details here are less precisely worked out than the insulin axis [23]. Oxidized LDL activates prostatic inflammatory signaling, stimulates cytokine release, and contributes to endothelial dysfunction and altered gland perfusion [23]. Some observational studies link statin use to reduced BPH prevalence and progression, but results are inconsistent and confounding is hard to rule out [23].

### 7.5 Integrative Mechanisms Linking MetS and BPH

The components of MetS converge on BPH through shared downstream pathways. Chronic systemic inflammation delivers pro-inflammatory cytokines to prostatic tissue [22]. MetS-associated oxidative stress—from mitochondrial dysfunction, hyperglycemia, and dyslipidemia—activates NF-κB and proliferative signaling in prostatic cells [22, 23]. Hormonal changes and inflammatory and oxidative inputs interact rather than adding up independently [22]. MetS-related vascular dysfunction may also reduce prostatic perfusion, promoting local hypoxia and angiogenic responses [23].

Lifestyle interventions that reduce visceral adiposity and improve insulin sensitivity address several of these pathways simultaneously and should probably be evaluated more rigorously in prospective BPH trials than they have been so far. Metformin and statins are plausible candidates for repurposing, though neither case is settled [22, 23].

## 8. Oxidative Stress Theory

### 8.1 Reactive Oxygen Species (ROS) in BPH Pathogenesis

Oxidative stress—excess ROS relative to antioxidant capacity—is consistently elevated in BPH tissue [1, 11, 18]. Superoxide, hydrogen peroxide, and hydroxyl radicals come from mitochondrial respiration, NADPH oxidase, and activated immune cells [11]. At moderate levels, ROS act as second messengers, activating MAPK, PI3K/Akt, and NF-κB in ways that promote proliferation and survival [11]. At higher concentrations, they cause lipid peroxidation, protein oxidation, and DNA damage [18]. This dose-dependency matters: the same molecules that facilitate normal signaling become damaging when produced in excess, which complicates the therapeutic logic of simply neutralizing all ROS.

The sources of elevated ROS in BPH are multiple: aging-related mitochondrial dysfunction, MetS components, and chronic prostatic inflammation each raise oxidative burden independently [18, 23].

### 8.2 Lipid Peroxidation and Cellular Damage

Polyunsaturated fatty acids in cell membranes are vulnerable to ROS, generating lipid peroxides and reactive aldehydes—MDA and 4-HNE—that accumulate in BPH tissue [2, 11]. These products disrupt membrane integrity, modify proteins and DNA, and activate additional inflammatory signaling [2]. Elevated MDA and depleted GSH in BPH relative to normal prostate are consistently replicated findings [2]. Reducing lipid peroxidation attenuates BPH in animal models, supporting a causal rather than merely associative role [2, 11].

**8.3 Antioxidant Defense Mechanisms**

SOD, catalase, and GPx activity are all reduced in BPH tissue, compounding the oxidative load [2, 11]. This probably reflects a combination of age-related decline in enzyme expression, depletion by chronic oxidative burden, and genetic variation [11, 18].

Nrf2 is the primary transcription factor driving adaptive antioxidant responses, inducing HO-1, NQO1, and glutathione S-transferases [2]. Nrf2 activity is reduced in BPH, which impairs this adaptive response [2, 19]. Sulforaphane and piceatannol, both Nrf2 activators, have shown preclinical promise in BPH prevention [2]—though the gap between preclinical antioxidant results and clinical benefit has been wide enough across medicine that I'd hold these findings loosely.

**8.4 Oxidative Stress and DNA Damage**

ROS preferentially attack guanine, generating 8-OHdG, which is markedly elevated in BPH tissue [11, 18]. Accumulated oxidative DNA damage shifts gene expression toward proliferative programs and away from pro-apoptotic ones, and activates p53/ATM/ATR pathways that can paradoxically induce SASP-producing senescence—connecting oxidative damage to the senescence accumulation discussed in Section 6.3 [11]. Declining DNA repair efficiency with age allows progressive accumulation of unrepaired lesions, which is one of the cleaner mechanistic links between aging and escalating BPH risk [18].

**8.5 Oxidative Stress Interactions with Other Pathogenic Mechanisms**

ROS activates NF-κB, which induces cytokine production and additional ROS generation, sustaining the oxidative-inflammatory cycle in BPH tissue [2, 11]. Androgens and estrogens modulate both ROS production and antioxidant enzyme expression; oxidative stress in turn alters hormone receptor expression and activity [1]. The MetS–BPH relationship is partly circular in this regard: MetS raises oxidative stress, while oxidative stress contributes to insulin resistance and metabolic dysfunction [18, 23].

Despite the coherent biology, clinical trials of dietary antioxidant supplementation have been consistently disappointing [11]. That's probably not a coincidence. Flooding the system with nonspecific antioxidants doesn't address which ROS sources are doing the damage or where they're doing it. If the oxidative stress theory is correct, useful interventions will need to be more targeted than vitamin E and selenium—which is a harder problem but a more honest framing of where the evidence actually sits.

## 9. Genetic and Epigenetic Factors

### 9.1 Familial Predisposition and Heritability

Genetic predisposition to BPH is well-documented. Men with an affected first-degree relative carry approximately four-fold elevated risk [17]. Twin concordance studies estimate heritability at 40–50%—substantial, and roughly comparable to other common complex diseases [17]. That familial clustering reflects inherited variation in genes governing androgen metabolism, inflammatory responsiveness, and growth factor signaling, the same pathogenic axes covered in preceding sections [13].

The genetic architecture is polygenic: many common variants, each with modest individual effects, collectively account for a meaningful share of population-level risk variation [13]. Identified loci don't explain the full heritability estimate, which means rare variants, gene-gene interactions, and gene-environment interactions are doing real work [13].

### 9.2 Genetic Polymorphisms in Hormone-Related Genes

Variants in androgen and estrogen metabolism genes are among the best-characterized risk factors. Polymorphisms in SRD5A2, including the V89L substitution, alter 5-AR activity and intraprostatic DHT levels; certain alleles associate with elevated susceptibility across multiple populations [13]. CAG repeat length in exon 1 of the androgen receptor gene modulates receptor transcriptional activity: shorter repeats confer higher AR activity and have been linked to increased BPH risk in some—though notably not all—study populations, likely reflecting gene-environment modification [13]. Variants in CYP17A1, CYP19A1 (aromatase), and HSD17B3 influence systemic androgen and estrogen levels and may affect susceptibility downstream [13]. Polymorphisms in ESR1 and ESR2 may shift the ERα-to-ERβ signaling balance and modulate prostatic growth responses to age-related estrogenic change [15].

### 9.3 Polymorphisms in Inflammatory and Oxidative Stress Genes

Given inflammation's central role in BPH, genetic variants modulating inflammatory pathway activity are plausible risk factors—and the data, while not definitive, are consistent with this [7]. Cytokine gene polymorphisms, including the IL-6 −174G/C promoter variant, have been associated with differential BPH susceptibility in several population studies [7]. Variants in TLR4, NF-κB pathway components, and COX-2/PTGS2 may modulate the prostatic inflammatory response to luminal and systemic stimuli [10]. Polymorphisms in SOD2, GPX1, CAT, and the Nrf2 pathway affect cellular capacity to neutralize ROS and may influence individual vulnerability to oxidative-stress-driven disease [10].

### 9.4 Epigenetic Regulation in BPH

Epigenetic modifications—DNA methylation, histone modifications, non-coding RNA expression—regulate gene expression without altering DNA sequence and accumulate progressively with aging in prostatic tissue [19]. In BPH, DNA methylation is significantly altered: growth-suppressor loci tend toward hypermethylation while pro-proliferative promoters are hypomethylated [19]. Dysregulation of HDACs and HATs

alters chromatin accessibility at genes governing proliferation, apoptosis, inflammation, and hormone responses [19].

MicroRNAs and long non-coding RNAs are differentially expressed in BPH tissue. MiR-21 is consistently upregulated, suppressing tumor suppressor genes and promoting proliferation; miR-145 is downregulated, removing a growth-inhibitory brake [8]. More recently, m6A RNA methylation has been implicated in regulating inflammatory pathways within BPH tissue—a post-transcriptional layer that hadn't been on anyone's radar until quite recently [8]. All of this points toward epigenetic mechanisms as plausible therapeutic targets, though none has been exploited clinically yet.

### 9.5 Gene-Environment Interactions

BPH almost certainly requires convergence of genetic susceptibility with environmental exposures—diet, physical activity, adiposity, chronic inflammatory stimuli [13, 19]. Men carrying variants that amplify inflammatory or androgenic responsiveness may be disproportionately vulnerable to the metabolic triggers described in preceding sections. Epigenetic mechanisms are the molecular interface through which diet, metabolic status, and environmental exposures translate into lasting alterations in gene expression [19]. The problem is that adequately powered prospective cohorts studying these interactions are largely absent. Until they exist, the interactions remain plausible and partially characterized rather than established.

## 10. Neuroendocrine and Emerging Mechanisms

### 10.1 Sympathetic Nervous System and Prostatic Innervation

The autonomic nervous system, particularly sympathetic innervation, regulates prostatic smooth muscle tone, cellular proliferation, and tissue remodeling [16]. Sympathetic nerve terminals release norepinephrine, acting on α1-ARs and beta-adrenergic receptors expressed by prostatic smooth muscle, stromal, and epithelial cells [16]. This means the sympathetic system influences both the static component of bladder outlet obstruction—gland volume—and the dynamic component, smooth muscle tone [16].

Age-related increases in sympathetic tone, reflected by elevated circulating catecholamines and enhanced prostatic adrenergic receptor expression in older men, may contribute directly to both BPH development and symptom severity [16].

### 10.2 Adrenergic Receptors in BPH

The α1A subtype predominates in prostatic smooth muscle and is the principal target of alpha-blocker therapy [16]. But α1-AR activation does more than contract smooth muscle—it also stimulates stromal cell proliferation and upregulates growth factor and extracellular matrix production through MAPK, PI3K/Akt, and RhoA/ROCK signaling [16]. Chronic adrenergic stimulation may therefore drive progressive enlargement, not just acute increases in urethral resistance [16]. Beta-adrenergic receptor activation has

opposing effects—smooth muscle relaxation, potential growth inhibition—and age-related shifts in the α-to-β adrenergic balance may favor disease progression [16].

### 10.3 Interactions with Hormonal and Inflammatory Mechanisms

Neuroendocrine and hormonal pathways are bidirectionally linked. DHT upregulates α1-AR density and sensitivity in prostatic tissue; adrenergic signaling in turn modulates androgen receptor activity [16]. Norepinephrine influences immune cell function and cytokine secretion, while chronic prostatic inflammation can alter innervation density and upregulate adrenergic receptor expression [7, 9]. The feedback loop this creates sustains neuroendocrine contributions to tissue remodeling even after other drivers have partially resolved.

### 10.4 Therapeutic Implications of Neuroendocrine Mechanisms

Alpha-blockers—tamsulosin, alfuzosin, doxazosin, terazosin—are now first-line therapy for symptomatic BPH, and they work fast: improvements in LUTS emerge within days to weeks, considerably quicker than 5-ARIs [27]. The MTOPS trial showed that combining an alpha-blocker with a 5-ARI reduces progression risk more effectively than either drug alone in men with larger prostates [25]. The CombAT trial confirmed this and demonstrated that dutasteride-tamsulosin combination was superior to either agent alone for symptom relief and prevention of acute urinary retention [26]. Whether beta-adrenergic modulators or agents targeting other neurotransmitter systems offer anything additional is an open question at the early-investigation stage.

### 10.5 Emerging Evidence: The Urinary Microbiome

The idea of a sterile urinary tract has largely collapsed. A resident urinary microbiome exists, differs substantially from bladder-adjacent gut microbiota, and is altered in men with LUTS and BPH—specifically, shifts away from commensal Lactobacillus toward pro-inflammatory taxa [12]. Proposed mechanisms include microbial metabolite production with systemic endocrine effects, local activation of prostatic inflammatory pathways through pattern recognition receptor engagement, and modulation of oxidative stress [12]. Diet, antibiotics, and metabolic status all shape microbiome composition, which places it as a possible mediating variable in gene-environment interaction.

I want to be careful not to overstate this: current evidence is largely observational and cross-sectional. The urinary microbiome is genuinely interesting, potentially modifiable, and still poorly characterized. It warrants prospective investigation but hasn't earned a strong mechanistic claim yet.

## 11. Discussion

The evidence reviewed across Sections 3–10 supports one conclusion: BPH is a multi-pathway disease whose natural history cannot be explained—or effectively modified—by targeting any single mechanism. Androgens are the necessary permissive substrate, but not sufficient. Chronic inflammation, metabolic dysregulation, stromal-epithelial paracrine signaling, stem cell senescence, oxidative stress, adrenergic tone, and the

emerging microbiome story each contribute independently and interact in self-amplifying loops.

The most therapeutically consequential interactions run through inflammation, metabolic syndrome, and androgens. DHT amplifies IL-6 and TNF-α production, which activate NF-κB and sustain the oxidative-inflammatory cycle; MetS components raise systemic cytokines that infiltrate the prostate, while hyperinsulinemia increases free androgens by suppressing SHBG. This hormonal-inflammatory-metabolic triad operates synergistically in most BPH patients, which is why monotherapy targeting one arm produces incomplete and often waning responses. Senescent SASP-producing cells create niche conditions that activate stem cell proliferation; inflammatory cytokines drive epithelial-mesenchymal transition and matrix remodeling. None of these processes operates in isolation.

Current combination therapy with alpha-blockers and 5-ARIs addresses the neuroendocrine-dynamic and androgenic-static components of obstruction [25, 26]. MTOPS demonstrates superiority over monotherapy in men with larger glands—but even this combination leaves metabolic and inflammatory pathways untouched. That gap is not a small one. Lifestyle interventions targeting visceral adiposity and insulin resistance act on multiple pathogenic axes at once and deserve evaluation in prospective BPH trials with mechanistic substudies [22, 23]. Pharmacological candidates with multi-pathway potential include metformin, statins, Nrf2 activators, and targeted anti-cytokine strategies [2, 19, 22, 23]—none yet evaluated in mechanism-stratified trials for BPH. The clinical trial infrastructure simply hasn't caught up with the mechanistic understanding.

The wide interindividual variability in BPH onset, progression rate, and treatment response almost certainly reflects differential activation of these pathogenic pathways. A man with early-onset BPH driven primarily by chronic prostatitis and NF-κB activation is probably not the same patient as one whose disease is predominantly metabolic and androgen-amplified, and treating them identically makes less sense the more clearly the mechanisms are understood. Biomarker stratification by dominant mechanism—serum or urine cytokine panels, adipokine profiles, urinary microbiome signatures, genetic risk scores—could support personalized treatment selection. None of this has been applied in clinical practice, which is a gap worth naming plainly.

The most important unresolved questions are causal sequence and clinical translation. Cross-sectional and preclinical data have mapped the interaction network with reasonable detail; what's missing is longitudinal human data establishing the temporal order in which pathogenic pathways activate, and which are primary versus reactive. Mechanism-specific biomarkers need prospective validation before they can guide patient selection. Randomized trials of anti-inflammatory and metabolic interventions need to be run. And the urinary microbiome needs characterization rigorous enough to determine whether it's a driver, a bystander, or a therapeutic target.

This review has the usual limitations of a narrative synthesis: selection bias in source inclusion, restriction to English-language publications, reliance on cross-sectional and preclinical data for many of the mechanistic claims, and no formal critical appraisal of individual study quality.

## 12. Conclusion

BPH is not a single-pathway disease—and the field's long-standing focus on androgens, however clinically productive, explains only a portion of why the disease starts and progresses. Chronic low-grade inflammation, stromal-epithelial paracrine signaling via FGFs, EGF, TGF-β, and IGFs, stem cell dysregulation, metabolic syndrome, oxidative stress, and adrenergic activity each act as independent and interacting drivers [7, 9, 10]. Genetic and epigenetic factors set individual susceptibility to these inputs, which accounts for the considerable variability in onset, progression rate, and treatment response [13, 19]. Microbiome data add another layer that isn't yet well-characterized [12].

Three things need to happen: trials of anti-inflammatory and metabolic interventions, biomarker-guided stratification of patients by dominant mechanism, and multi-omics prospective cohorts built to establish the causal order of pathway activation. The mechanistic picture is detailed enough to justify all three. The clinical trials haven't followed.

## References

1. Lepor H. Pathophysiology of benign prostatic hyperplasia in the aging male population. Rev Urol. 2005;7(Suppl 4):S3–S12. PMID: 16986052.
2. Eid BG, Abdel-Naim AB. Piceatannol attenuates testosterone-induced benign prostatic hyperplasia in rats by modulation of Nrf2/HO-1/NF-κB axis. Front Pharmacol. 2020;11:614897. doi:10.3389/fphar.2020.614897. PMID: 33519479.
3. Nickel JC, Roehrborn CG, O'Leary MP, Bostwick DG, Somerville MC, Rosen RC. The relationship between prostate inflammation and lower urinary tract symptoms: examination of baseline data from the REDUCE trial. Eur Urol. 2008;54(6):1379–84. doi:10.1016/j.eururo.2007.11.026.
4. Urgesa HE, Leta TA, Feyisa TO, Bati AH, Tulu KT, Nasi BA, et al. Prevalence and association of metabolic syndrome components with benign prostate hyperplasia. Cardiovasc Diabetol Endocrinol Rep. 2026;12:5. doi:10.1186/s40842-025-00266-0.
5. Kwon OJ, Xin L. Prostate epithelial stem and progenitor cells. Am J Clin Exp Urol. 2014;2(3):209–18. PMID: 25374923.
6. Bielkina IO, Smolienko NP, Korenieva YeA, Marakhovskyi IV, Tkachenko NP, Horbach OV. Vitamin D and saw palmetto fruit extract in experimental prostate pathology. Probl Endokryn Patol. 2025;82(3):20–28. doi:10.21856/j-PEP.2025.3.03.

7. De Nunzio C, Presicce F, Tubaro A. Inflammatory mediators in the development and progression of benign prostatic hyperplasia. Nat Rev Urol. 2016;13(10):613–26. doi:10.1038/nrurol.2016.168. PMID: 27686153.
8. Xie Q, Zhao H, Yang X, Zhang H, Liu H, Pan J, et al. The emerging role of m6A methylation in prostate-related diseases: mechanisms and clinical implications. Front Immunol. 2026;17:1685015. doi:10.3389/fimmu.2026.1685015.
9. Inamura S, Terada N. Chronic inflammation in benign prostatic hyperplasia: pathophysiology and treatment options. Int J Urol. 2024;31(9):968–74. doi:10.1111/iju.15518. PMID: 38934050.
10. Oseni SO, Karzai F, Dahut W, VanderWeele D, Madan RA. The molecular basis and clinical consequences of chronic inflammation in prostatic diseases: prostatitis, benign prostatic hyperplasia, and prostate cancer. Cancers (Basel). 2023;15(12):3110. doi:10.3390/cancers15123110. PMID: 37370720.
11. Roumeguere T, Sfeir J, El Rassy E, Albisinni S, Van Antwerpen P, Boudjeltia KZ. Oxidative stress and prostatic diseases. Mol Clin Oncol. 2017;7(5):723–8. doi:10.3892/mco.2017.1413. PMID: 29130996.
12. Zhang Y, Wang H, Yan R, Wang K, Man J, Yang L. Research advances on the urinary microbiome in non-infectious urinary tract diseases: from community composition to clinical prospects. Front Cell Infect Microbiol. 2026;16:1728182. doi:10.3389/fcimb.2026.1728182.
13. Devlin CM, Simms MS, Maitland NJ. Benign prostatic hyperplasia – what do we know? BJU Int. 2021;127(4):389–99. doi:10.1111/bju.15229. PMID: 32862511.
14. Dwivedi S, Sachan A, Upadhyay P, et al. NF-κB (p65, p50), IL-18, and IL-10 as therapeutic targets in prostate cancer and BPH: molecular insights into inflammation-driven pathogenesis. Asian Pac J Cancer Prev. 2026;27(1):381–8. doi:10.31557/APJCP.2026.27.1.381. PMID: 41569207.
15. Fejsa Levakov A, Mocko Kaćanski M, Vucković N, Zivojinov M, Amidzić J, Ilić Sabo J. The expression and localization of estrogen receptor beta in hyperplastic and neoplastic prostate lesions. Vojnosanit Pregl. 2015;72(10):906–13. doi:10.2298/VSP131022069F. PMID: 26665557.
16. Cao Y, Zhang S, Zou S, Xia X. Immune cell proinflammatory microenvironment and androgen-related metabolic regulation during benign prostatic hyperplasia in aging. Front Immunol. 2022;13:842008. doi:10.3389/fimmu.2022.842008. PMID: 35359984.
17. Partin AW, Page WF, Lee BR, Sanda MG, Miller RN, Walsh PC. Concordance rates for benign prostatic disease among twins suggest hereditary influence. Urology. 1994;44(5):646–50. doi:10.1016/S0090-4295(94)80197-5. PMID: 7526523.
18. Xie F, Kang Z, Zhao X, et al. Association between oxidative balance score and benign prostatic hyperplasia: an analysis based on the NHANES from 2003 to

2008. Aging Male. 2026;29(1):2611694. doi:10.1080/13685538.2025.2611694. PMID: 41510672.
19. Xiang J, Zheng Y, Chen D, Zeng Y, Zhang J, Chang D, et al. The pathogenesis of benign prostatic hyperplasia and the roles of Prdx3, oxidative stress, pyroptosis and autophagy: a review. Front Oncol. 2025;15:1579539. doi:10.3389/fonc.2025.1579539.
20. Pan Y, Song Q, Lai B, Ma H. Advances in the identification of novel cell signatures in benign prostatic hyperplasia and prostate cancer using single-cell RNA sequencing. Front Immunol. 2026;16:1684895. doi:10.3389/fimmu.2025.1684895.
21. Gupta A, Gupta S, Pavuk M, Roehrborn CG. Anthropometric and metabolic factors and risk of benign prostatic hyperplasia: a prospective cohort study of Air Force veterans. Urology. 2006;68(6):1198–205. doi:10.1016/j.urology.2006.09.034. PMID: 17169643.
22. Fu X, Jiang C, Li Y, et al. Association between metabolic syndrome and benign prostatic hyperplasia: the underlying molecular connection. Life Sci. 2024;358:123192. doi:10.1016/j.lfs.2024.123192. PMID: 39488266.
23. Castelli G, Middleman B, Baca SM. Metabolic syndrome and prostatic disease: potential role of polyphenols in preventive strategies. Int Braz J Urol. 2016;42(3):422–30. doi:10.1590/S1677-5538.IBJU.2015.0095. PMID: 27286103.
24. Gudmundsson J, Sigurdsson JK, Stefansdottir L, et al. Genome-wide associations for benign prostatic hyperplasia reveal a genetic correlation with serum levels of PSA. Nat Commun. 2018;9(1):4568. doi:10.1038/s41467-018-06920-9. PMID: 30410027.
25. McConnell JD, Roehrborn CG, Bautista OM, et al.; MTOPS Research Group. The long-term effect of doxazosin, finasteride, and combination therapy on the clinical progression of benign prostatic hyperplasia. N Engl J Med. 2003;349(25):2387–98. doi:10.1056/NEJMoa030656. PMID: 14681504.
26. Roehrborn CG, Siami P, Barkin J, et al.; CombAT Study Group. The effects of combination therapy with dutasteride and tamsulosin on clinical outcomes in men with symptomatic benign prostatic hyperplasia: 4-year results from the CombAT study. Eur Urol. 2010;57(1):123–31. doi:10.1016/j.eururo.2009.09.035. PMID: 19825505.
27. European Association of Urology. EAU Guidelines on Non-neurogenic Male LUTS, including Benign Prostatic Obstruction (BPO). Arnhem: EAU Guidelines Office; 2024.
28. Ferrari R. Writing narrative style literature reviews. Med Writ. 2015;24(4):230–5. doi:10.1179/2047480615Z.000000000329.

**Information about the authors:**

**Global Insights in Biomedical & Multidisciplinary Research (GIBMR)**
**Volume 01, Issue 02, April-2026**
**Available Online at:** https://biomedglobe.com/index.php/gibmr
**ISSN (Online):** 3054-5900

© KHUDAYBERDIEV Kh.B. — Tashkent State Medical University; Republican Specialized Scientific and Practical Medical Center of Urology. Assistant Professor. ORCID: https://orcid.org/0000-0003-2174-5426. Email: hhbnick@gmail.com
© SOLIEV T.Kh. — Republican Specialized Scientific and Practical Medical Center of Urology. Urologist, PhD.